← Compound index
COMPOUND RECORD / AWE18

AWE18Пептидомиметик AWE18

An experimental cyclic peptidomimetic containing alanine, glutamate and tryptophan. Researchers studied its effects on hematopoiesis, the formation of blood cells.

Source linked

What the studies found

Animal research · 2016

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Study of multiple preparations

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Study notes · methods, sources and limitations

Participants or model Intact mice, donor marrow and irradiated recipient-mouse colony assays

Important limitations

  • AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported. Related publications may share experiments; source count is not independent-study count.

ChemMedChem · Publication record

Original source or citation ↗

Study results and tables ↗

Review of earlier studies · 2023

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Study of multiple preparations

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Study notes · methods, sources and limitations

Participants or model Source-specific experimental population

Important limitations

  • Independent replication and full risk-of-bias appraisal remain unresolved. No personalized treatment or safety conclusion follows from this record.

International Journal of Molecular Sciences 24(17):13534 · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About AWE18

Research background

Experimental cyclic Ala/Glu/Trp peptidomimetic discussed in the development literature. Its evidence must remain separate from CP-88.

Conference sources and research collaborators ↗

Compound class
Peptide / preparation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

See preparation-specific records; human benefit not established here

Study methods

Source-specific designs and limitations below

Independent replication

Related reports are not automatically independent evidence

Source access

Linked publications; access and review scope shown per record

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The cyclic-peptide platform paper is available. The link between the AWE18 development code and compound 3 remains uncertain, and human efficacy and toxicology data remain open questions.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2013 · EP2046778B1 · Cyclic glutamyl-tryptophan scaffold patentPlatform context · A tested cyclic compound reportedly increased antibody titers by 74%

Reported findings

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Protein-antigen response
A tested cyclic compound reportedly increased antibody titers by 74%A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result
Oral activity comparison
Some cyclic analogues retained oral analgesic activity where comparator peptides did notDifferent neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective
All reported results, comparisons and limitations →

Platform context. The family concerns cyclic piperazine-based immunomodulatory compounds related to the chemistry discussed for CP-88 and AWE18.

The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.

Publication
EP2046778B1 ↗ · 2013-12-04
Earliest priority / filing
2006-08-04 / 2007-08-01
Original applicant / assignee
Manus Pharmaceuticals Canada Ltd
Indexed status
Active · checked 2026-11-06
Patent family
38996830 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Multifunctional bioactive compounds

Inventors: Vladislav I. Deigin.

EP2046778B1 · US8637521B2 · JP5357022B2 · CN101511823B · AU2007280995C1 · BRPI0714616A2 · CA2659875C · EA018548B1 · MX2009001351A · WO2008014613A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Experiment described in a patent · 2013

Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Study notes and original source
2013Patent / reported experimentsFull text available

Cyclic glutamyl-tryptophan scaffold patent — EP2046778B1

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladislav I. Deigin · EP2046778B1 · patent family 38996830

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Results and tables

Reported patent results

Reported findings

One cyclic platform compound enhanced an antigen-response measure, while other experiments concerned analgesia and different molecules.

Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.

Population or model Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.

Results · Examples covering platform immune response and oral neuropeptide comparisons; exact candidate mapping unresolved.
MeasureResultComparison, timing and statistics
Protein-antigen responseA tested cyclic compound reportedly increased antibody titers by 74%A model-antigen experiment; not autoimmune clinical efficacy or a verified AWE18/CP-88 result
Oral activity comparisonSome cyclic analogues retained oral analgesic activity where comparator peptides did notDifferent neuropeptide constructs; not evidence that every cyclic immune peptide is orally effective

Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
Platform patent experiments across cyclic glutamyl-tryptophan compounds in mice and cells; exact mapping to AWE18 or CP-88 remains unverified.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The candidate codes are not an exact verified claim match here. Treat this as platform context, not proof that a particular candidate is covered or clinically effective.
  • Results belong to the specifically tested compounds. Candidate-code uncertainty prevents assigning these values to CP-88 or AWE18, and animal antigen responses are not clinical treatment benefits.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2016

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Study notes and original source
2016Animal / experimentalFull text available

Chemical Platform for the Preparation of Synthetic Orally Active Peptidomimetics with Hemoregulating Activity.

Preparation-specific research; no equivalence inferred

Deigin V, Ksenofontova O, Khrushchev A, Yatskin O, Goryacheva A, Ivanov V. · ChemMedChem

Five cyclic analogues, numbered 3–7, were synthesized; three showed activity in experimental hematopoietic assays. Normal-marrow stimulation and post-irradiation recovery differ. Oral activity is not a pharmacokinetic measurement.

Population / setting
Intact mice, donor marrow and irradiated recipient-mouse colony assays
Source reviewed
Full primary text checked: compound 3 is the alanine cyclic scaffold later discussed as AWE18 in the 2023 platform review. Experimental comparisons concern mice and irradiated marrow; supporting raw data not independently reanalyzed.
Study limitations
  • AWE18 is a later development label; do not generalize the activity of other numbered analogues to it. No human trial is reported.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Review of earlier studies · 2023

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Study notes and original source
2023ReviewFull text available

Advancement from Small Peptide Pharmaceuticals to Orally Active Piperazine-2,5-dion-Based Cyclopeptides

Defined synthetic peptide / analogue

Vladislav Deigin, Natalia Linkova, Olga Volpina · International Journal of Molecular Sciences 24(17):13534

Development-group review connecting small peptides with cyclic peptidomimetics, including AWE18. AWE18 and CP-88 are separate candidates. Review descriptions of oral activity are not independent clinical trials.

Population / setting
Source-specific experimental population
Source reviewed
Review full text retrieved via Europe PMC. Primary compound-specific studies require separate appraisal.
Study limitations
  • Independent replication and full risk-of-bias appraisal remain unresolved.
  • No personalized treatment or safety conclusion follows from this record.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗